European appeals board revokes Novo patent on cardiovascular use of semaglutide
Generic makers gain ground as another layer of semaglutide protection falls, per Life Sciences IP Review. Full story is behind a paywall.
Recap by typeshit. Full story at Life Sciences IP Review.